Generic drugmaker Mylan NV said on Tuesday reevaluation of its portfolio of medicines will continue next year and cautioned of a hit to revenue, and its shares nearly 6%.
Pfizer Inc reported a higher-than-expected third-quarter profit on Tuesday on increased sales of cancer drug Ibrance and a strong launch of new heart medicine Vyndaqel, prompting the largest U.S. drugmaker to lift its earnings forecast for the year.
Sept 10 The U.S. Food and Drug Administration
has approved Xeris Pharmaceuticals Inc's glucagon
therapy that aims to treat severely low sugar levels in diabetes
patients, the drugmaker said on Tuesday.
Retrophin Inc said on Thursday it was discontinuing the late-stage study for its rare neurological disorder treatment after it failed to improve patients' ability to conduct daily activities such as eating and walking, sending shares down 30%.
Medtronic Plc beat analysts' estimates for quarterly profit on Tuesday, boosted by higher demand for its surgical instruments and diabetes devices, and the medical device maker raised its forecast for full-year adjusted profit as well.
The U.S. Food and Drug Administration on Friday approved Celgene Corp's Inrebic to treat certain rare forms of bone marrow cancer called myelofibrosis, making it the second approved drug to treat the disease.
Deciphera Pharmaceuticals Inc's shares more than doubled on Tuesday after the drugmaker said its treatment helped stomach cancer patients live longer without their disease worsening in a late-stage study.
Health insurer Humana Inc raised its 2019 profit forecast on Wednesday and beat second-quarter earnings estimates, as it reined in costs and recorded higher revenue from its unit that sells Medicare Advantage health plans.